Niraparib: First Global Approval

Scott, Lesley J.

doi:10.1007/s40265-017-0752-y

2017-05-04

282

PRE

Scott, Lesley J. *

DOI：10.1007/s40265-017-0752-y

原文链接

原文求助

摘要

En 中文

Oral niraparib, a highly-selective, potent poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, is approved in the USA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. It is also under regulatory review in the EU for use in maintenance treatment in patients with platinum-sensitive, recurrent epithelial ovarian cancer who are in response to platinum-based chemotherapy. In the multinational, phase 3 NOVA trial in adult patients with platinum-sensitive, recurrent ovarian cancer, niraparib significantly prolonged median progression-free survival, irrespective of the presence or absence of a germline BRCA (gBRCA) mutation and irrespective of the presence or absence of homologous recombinant deficiency. Niraparib is also in development for use in other solid tumours, including breast and prostate cancer. This article summarizes the milestones in the development of niraparib leading to its first global approval for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

Keyword:

POLYMERASE INHIBITOR

HUMAN LUNG

MK-4827

THERAPY

AI总结

对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

Drugs

IF:

14.4

论文数:

8.4K

被引数:

2.3W

机构

springer nature

学者数:

108

论文数: 516

被引数: 0

引用论文

Tight junction regulation in celiac disease: role of larazotide acetate

Minerva Gastroenterology

IF0

2022-03-01

PREAI

Angelo ARMANDI; Rinaldo PELLICANO; Gian P. CAVIGLIA

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

Yearbook of Vascular Surgery

IF0

2009-01-01

PREAI

G.L. Moneta

Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2015-03-11

147

PREAI

Jones, Philip; Wilcoxen, Keith; Rowley, Michael; Toniatti, Carlo

A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study)

CANCER RESEARCH

IF16.6

2016-02-15

PREAI

Balmana, J.; Tryfonidis, K.; Audeh, W.; Goulioti, T.; Slaets, L.; Agarwal, S.; Lema, N.; Cameron, D.; Turner, N.

Energy metabolism of skeletal muscle containing cyclocreatine phosphate. Delay in onset of rigor mortis and decreased glycogenolysis in response to ischemia or epinephrine.

Journal of Biological Chemistry

IF0

1980-05-01

OAAI

T.M. Annesley; J.B. Walker

The role of basolateral amygdala in the regulation of stress-induced phosphorylated extracellular signal-regulated kinase expression in the hippocampus

Neuroscience

IF0

2012-11-01

PREAI

B. Jeon; Y.K. Hwang; S.-Y. Lee; D. Kim; C. Chung; J.-S. Han

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

INVESTIGATIONAL NEW DRUGS

IF2.7

2017-03-16

OAAI

van Andel, Lotte; Zhang, Z.; Lu, S.; Kansra, V.; Agarwal, S.; Hughes, L.; Tibben, M. M.; Gebretensae, A.; Lucas, L.; Hillebrand, M. J. X.; Rosing, H.; Schellens, J. H. M.; Beijnen, J. H.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer 铂敏感的复发性卵巢癌的尼拉帕尼维持治疗

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2016-12-01

1.9K

OAAI

Mirza, M. R.; Monk, B. J.; Herrstedt, J.; Oza, A. M.; Mahner, S.; Redondo, A.; Fabbro, M.; Ledermann, J. A.; Lorusso, D.; Vergote, I.; Ben-Baruch, N. E.; Marth, C.; Madry, R.; Christensen, R. D.; Berek, J. S.; Dorum, A.; Tinker, A. V.; du Bois, A.; Gonzalez-Martin, A.; Follana, P.; Benigno, B.; Rosenberg, P.; Gilbert, L.; Rimel, B. J.; Buscema, J.; Balser, J. P.; Agarwal, S.; Matulonis, U. A.

PARP Inhibitors in Reproductive System Cancers: Current Use and Developments

DRUGS

IF14.4

2017-01-11

OAAI

Coyne, Geraldine O'Sullivan; Chen, Alice P.; Meehan, Robert; Doroshow, James H.

Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2009-10-29

328

PREAI

Jones, Philip; Altamura, Sergio; Boueres, Julia; Ferrigno, Federica; Fonsi, Massimiliano; Giomini, Claudia; Lamartina, Stefania; Monteagudo, Edith; Ontoria, Jesus M.; Orsale, Maria Vittoria; Palumbi, Maria Cecilia; Pesci, Silvia; Roscilli, Giuseppe; Scarpelli, Rita; Schultz-Fademrecht, Carsten; Toniatti, Carlo; Rowley, Michael

查看更多内容